Table I.

Association of tumor infiltrating lymphocytes with clinicopathological characteristics of breast cancer patients.

Characteristics	Total N	TILs low N (%)	TILs high N (%)	P-value
Age				0.976
<50 years	26	18 (69.2)	8 (30.8)
≥50 years	46	32 (69.6)	14 (30.4)
Tumor size				0.100
<2 cm	30	24 (80.0)	6 (20.0)
≥2 cm	42	26 (61.9)	16 (38.1)
Lymph node				0.409
Negative	38	28 (73.7)	10 (26.3)
Positive	34	22 (64.7)	12 (35.3)
Histological grade				0.030
Low (I and II)	40	32 (80.0)	8 (20.0)
High (III)	32	18 (56.3)	14 (43.8)
ER				0.006
Negative	23	11 (47.8)	12 (52.2)
Positive	49	39 (79.6)	10 (20.4)
HER2 status				0.047
Negative	48	37 (77.1)	11 (22.9)
Positive	24	13 (54.2)	11 (45.8)
Ki-67				0.113
<20%	33	26 (78.8)	7 (21.2)
≥20%	39	24 (61.5)	15 (38.5)
Molecular subtype				0.012
Luminal	37	31 (83.8)	6 (16.2)
Her2+	24	13 (54.2)	11 (45.8)
Triple-negative	11	5 (45.5)	6 (54.5)

TILs, tumor infiltrating lymphocytes; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2.